Parasite | Eso | Sto | Cancer | ESD
ÀϽÃ: 2015³â 9¿ù 12ÀÏ - 13ÀÏ
Àå¼Ò: È«Àºµ¿ ±×·£µå ÈúÆ° È£ÅÚ
1. Debate on endoscopic management of lower GI neoplasia
¼øõÇâ´ëÇб³ °íºÀ¹Î ¼±»ý´Ô²²¼´Â ¸Å¿ì ÁÁÀº Áõ·ÊµéÀ» º¸¿©ÁÖ¸é¼ unclear pit pattern µîÀ» º¸À̴ ȯÀÚ¿¡¼ EUS¸¦ Ãß°¡ÇÏ¿© ½É´Þµµ ¿¹Ãø·üÀ» ³ôÀÏ ¼ö ÀÖ¾ú´Ù°í ¹ßÇ¥ÇÏ¿´½À´Ï´Ù. Àú´Â EUS îñ ¹é»ö±¤³»½Ã°æ, »ö¼Ò³»½Ã°æ, È®´ë³»½Ã°æ µîÀÇ ¼Ò°ßÀ» ¸ðµÎ È®º¸ÇÏ¿´±â ¶§¹®¿¡ ±× »óȲ¿¡¼ EUSÀÇ Á¤È®µµ´Â ¾ö¹ÐÈ÷ ¸»Çϸé EUSÀÇ Á¤È®µµ°¡ ¾Æ´Ï¶ó '¸ðµç °ÍÀ» Á¾ÇÕÇÑ Á¤È®µµ'¶ó°í ºÎ¸£´Â °ÍÀÌ Å¸´çÇÏ´Ù°í commentÇÏ¿´½À´Ï´Ù.
Keio ´ëÇÐÀÇ Naoki Hosoe´Â CLE (confocal laser endocytoscopy)¸¦ ¼Ò°³ÇÏ¿´½À´Ï´Ù. ¿¬¼¼´ë½ÅÃ̼¼ºê¶õ½º º´¿ø°ú ºÐ´ç Â÷º´¿ø µî¿¡µµ µµÀԵǾú½À´Ï´Ù. ¾ÆÁ÷Àº ¿¬±¸´Ü°èÀÎ ¸ð¾çÀÔ´Ï´Ù.
CLE has been first reported in 2004. Recently, it can be performed with two devices: one integrated into endoscope (e-CLE; Pentax), and one using a mini-probe through the scope (p-CLE; Cellvizio, France). CLE is based on tissue illumination with a low-power laser with subsequent detection of the fluorescence of light reflected from the tissue through a pinhole. Confocal imaing can be based on tissue reflectance or fluorescence. The fluorescent contrast agents most commonly used for CLE can be administered intravenously (fluorescein sodium, AK Fluor; Akorn Pharmaceutical, Lake Forest, Ill) or topically (Acriflavin; Sigma Pharmaceuticals, Clayton, Victoria, Australia), tetracycline, or cresyl violet (AnaSpec, Inc, San Jose, CA) through a spraying catheter."
°è¸í´ëÇб³ÀÇ ±èÀº¼ö ¼±»ý´ÔÀº screeningÀ» Çϸé 10 mm ÀÌÇÏÀÇ rectal NE tumorÀÇ ºñÀ²ÀÌ ÇöÀúÈ÷ ³ô¾ÆÁø´Ù´Â À̾߱â·Î °ÀǸ¦ ½ÃÀÛÇϼ̽À´Ï´Ù.
³»½Ã°æÀû Ä¡·á¹æ¹ýÀº ´Ù¾çÇѵ¥ ESD¿Í modified EMRÀÇ ¼ºÀûÀÌ ºñ½ÁÇÏ´Ù´Â Á¡À» ÀçÄ¡ÀÖ´Â ½½¶óÀ̵å·Î ½±°Ô º¸¿©Áּ̽À´Ï´Ù. µ¿°æ¾Ï¼¾ÅÍÀÇ ÀϺ»ÀÎ ÀÇ»ç´Â rectal carcinoid¸¦ ESDÇÒ ÇÊ¿ä°¡ ¾ø´Ù°í comment ÇÏ¿´½À´Ï´Ù (¾à°£ °Ç¹æÁø ÀÚ¼¼·Î... »ßµüÇÏ°Ô ¼¼...).
NCCN guideline (2015)¿¡¼´Â "<1cm, No follow-up reguired"·Î µÇ¾î ÀÖ°í, ¿¬¼¼´ë ¿¬±¸(Kim DH. Digest Dis Sci 2014)¿¡µµ À§ÇèÀÎÀÚ°¡ ¾ø´Â ȯÀÚ¿¡¼ intensive surveillance°¡ ÇÊ¿äÇÏÁö ¾Ê´Ù°í ¾ð±ÞµÇ¾î ÀÖ½À´Ï´Ù.
±èÀº¼ö ¼±»ý´ÔÀº 5 mm grade 1 rectal NE tumorÀÇ EMR Á¶Á÷¿¡¼ lymphatic invasionÀÌ ÀÖ¾î ¼ö¼úÀ» ±ÇÇÏ¿´°í local lymph node metastasis°¡ ÀÖ¾ú´ø Áõ·Ê¸¦ ¼Ò°³Çϼ̽À´Ï´Ù. ¼¿ï¾Æ»êº´¿ø¿¡¼´Â Á÷Àå À¯¾ÏÁ¾ ³»½Ã°æÄ¡·á ÈÄ Á÷Àå¿· ¸²ÇÁÀýÀÌ ÃµÃµÈ÷ (7³â) Ä¿Áø °ÍÀ» ¹ß°ßÇÏ°í ¼ö¼úÇϱ⵵ Çß½À´Ï´Ù (Kim SH. Intest Res 2015). Áï ÀüÀÌ°¡ À־ ¸Å¿ì õõÈ÷ ÀÚ¶õ´Ù´Â °ÍÀÔ´Ï´Ù.
°í¹ÎÀÌ ¾Æ´Ò ¼ö ¾ø½À´Ï´Ù. ³»½Ã°æÀ¸·Î Àß ÀýÁ¦µÈ 1 cm ÀÌÇÏÀÇ ÀÛÀº À¯¾ÏÁ¾ÀÇ º´¸®°Ë»ç¿¡¼ À§ÇèÀÎÀÚ°¡ ¾øÀ¸¸é ÃßÀû°üÂûÀ» ÇÏÁö ¸»ÀÚ´Â °¡À̵å¶óÀΰú ¿¬±¸°¡ °è¼Ó ¹ßÇ¥µÇ°í ÀÖ½À´Ï´Ù. ±×·±µ¥ ÃßÀû°üÂû ´ë»óÀÌ ¾Æ´Ñ ȯÀÚ¿¡¼ °£È¤ ÀüÀÌ(metastasis)°¡ ¹ß°ßµË´Ï´Ù. 5³â ÀÌÈÄ¿¡ ¹ß°ßµÇ´Â °æ¿ìµµ ÀÖ½À´Ï´Ù. µµ´ëü ´©±¸¸¦ ¾ðÁ¦±îÁö ÃßÀû°üÂû ÇÏ¿©¾ß ÇÒ±î¿ä? 1¸íµµ ³õÄ¡Áö ¾ÊÀ¸·Á¸é ³Ê¹« ¸¹Àº »ç¶÷ÀÌ ³Ê¹« ¸¹Àº °Ë»ç¸¦ ¹Þ¾Æ¾ß ÇÕ´Ï´Ù. Risk benefit ¿¬±¸°¡ ÇÊ¿äÇÏ´Ù°í »ý°¢µË´Ï´Ù. ¾ÆÁ÷ ¸íÈ®È÷ Á¤¸®µÇÁö ¸øÇÑ À̽´ÀÔ´Ï´Ù.
2. Management of technically difficult endoscopic submucosal dissection for colorectal tumors - Shiro Oka (˪ ò¤ÕÍ, Hiroshima University)
Oka ¼±»ý´ÔÀÇ Hiroshima ´ëÇÐÀº ÀϺ» ´ëÀå³»½Ã°æ°èÀÇ º¸½ºÀÎ Tanaka ¼±»ý´ÔÀÌ °è½Ê´Ï´Ù. ±×·¡¼ÀÎÁö colon ESD Áõ·Ê°¡ ¸Å¿ì ¸¹¾Ò½À´Ï´Ù. »óȲ¿¡ µû¶ó ´Ù¾çÇÑ Àü·«À» »ç¿ëÇÏ°í ÀÖ¾ú½À´Ï´Ù.
È¿À²ÀûÀÎ ½Ã¼úÀ» À§ÇÏ¿© µÎ °¡Áö ¹æ¹ýÀ» »ç¿ëÇÑ´Ù°í ÇÕ´Ï´Ù. (1) Single use splitting tube (single balloon overtube, sigle balloon enteroscopy technique°ú ºñ½ÁÇÏ¿´½À´Ï´Ù), (2) Needle-in technique using Dual knife¿´½À´Ï´Ù.
Á¦°Ô´Â Needle-in techniqueÀÌ ÀλóÀûÀ̾ú½À´Ï´Ù. Fibrosis°¡ ÀÖÀ» ¶§ È¿°úÀûÀ̶ó°í ÇÕ´Ï´Ù.
3. Molecular imaging and theranostics for GI cancers - Jung-Joon Min (Department of Nuclear Medicine, Chonnam National University Hwasun Hospital)
Precision medicine - °³ÀÎ À¯ÀüÀÚ Á¤º¸¿¡ ±Ù°ÅÇÑ °³º°ÈµÈ Ä¡·á
Theranostics - Targeted therapeutic°ú Companion diagnostic¸¦ ÇÕÇÑ °³³äÀÌ´Ù.
Repebody is a binding scaffold based on variable lymphocyte receptors, which are nonimmunoglobulin antibodies composed of leucine-rich repeat modules in jawless vertebrates. Rapebody can be developed against variety of epitopes by module engineering. In this study, EGFR-specific repebody (RBEGFR) was developed to visualize the status of receptor expression and to prevent ligand binding that may inhibit autophosphorylation and downstream intracellular signaling.
ÇÙÀÇÇаú ¼±»ý´Ô²²¼ ³»½Ã°æÇÐȸ¿¡¼ °ÀÇÇÑ Á¡ÀÌ ÀλóÀûÀ̾ú½À´Ï´Ù. ƯÈ÷ ¼Òȱ⳻°ú ÀÌ¿Ï½Ä ±³¼öÀÇ µµ¿òÀÌ ÄÇ´Ù°í ¸î Â÷·Ê À̾߱â Çϼ̽À´Ï´Ù. Àü³²´ëÇб³¿¡¼´Â ¿©·¯ Àü¹®°¡ »çÀÌÀÇ colloborationÀÌ Àß µÇ°í ÀÖ´Â °Í °°½À´Ï´Ù. ºÎ·¯¿î ÀÏÀÔ´Ï´Ù.
4. Case-based discussion (°¡Å縯´ëÇб³ ¹ÚÀç¸í)
µÎ °³ÀÇ ¼±Á¾À¸·Î ÀǷڵǾúÀ½. AFI¿¡¼ µÎ º´¼Ò°¡ ¿¬°áµÇ¾î º¸¿©¼ single piece·Î ESD¸¦ ÇÏ¿´°í 8 cm Á¡¸·¾Ï º´¸®ÇÐÀû ¿ÏÀüÀýÁ¦·Î ³ª¿Ô½À´Ï´Ù. ¹ÚÀç¸í ¼±»ý´ÔÀº AFI°¡ multiple cancer¸¦ ¹ß°ßÇϴµ¥ µµ¿òµÈ´Ù´Â ¿¬±¸°á°ú¸¦ ¹ßÇ¥ÇÑ ¹Ù ÀÖ½À´Ï´Ù. Superficial spreading type º´¼Ò°¡ 8 cmÀÌ°í Á¶Á÷°Ë»ç°¡ adenocarcinoma¿´´Ù¸é °ú¿¬ ESD¸¦ ÇßÀ»Áö ±Ã±ÝÇß½À´Ï´Ù. Àú´Â ¼ö¼úÀ» º¸³¾ °Í °°½À´Ï´Ù. Pre-ESD diagnostic group°ú post-ESD diagnostic groupÀÇ Â÷ÀÌ°¡ Áß¿äÇÒ °Í °°½À´Ï´Ù. ÀÌ È¯ÀÚ´Â pre-ESD diagnostic groupÀÌ adenoma¿´±â¿¡ ESD°¡ ¼±ÅÃµÈ °ÍÀÔ´Ï´Ù. ESD °ü·Ã ÀڷḦ ÀÐÀ» ¶§¿¡´Â ÀÌ Á¡À» ÁÖÀÇÇØ¾ß ÇÒ °Í °°½À´Ï´Ù.
Åä¿äÀÏ Àú³á Gala Dinnerµµ ÁÁ¾Ò½À´Ï´Ù.
5. Treatment Strategy and Limitations of Standard ESD (2015-9-13 (ìí) 7:30-8:10 Breakfast with the Experts ¼¼¼Ç) - IDEN 2015
6. Do we have to be more aggressive in therapeutic endoscopy?
1) Current stuatus of NOTES in Europe - Silvana Perretta (University of Strsabourg, France)
NOTES ȤÀº advanced endoscopy¶ó´Â À̸§À» ½ÃÇàµÇ´Â ¸¹Àº ½Ã¼úÀ» º¸¿©ÁÖ¾ú½À´Ï´Ù. Àú´Â ¾Æ·¡ ½½¶óÀ̵尡 °¡Àå ÁÁ¾Ò½À´Ï´Ù. ±×·¸½À´Ï´Ù. °ú°Å ¼ö¼úÇÏ´ø º´ÀÌ »ó´ç¼ö ³»½Ã°æÀ¸·Î Ä¡·áÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ±×·¯³ª, ¼ö¼úÇÏ´ø º´ÀÌ ¸ðµÎ ³»½Ã°æ Ä¡·á·Î ¹Ù²ð °Í °°Áö´Â ¾Ê½À´Ï´Ù. µÇ´Â °ÍÀÌ ÀÖ°í ¾È µÇ´Â °ÍÀÌ ÀÖ½À´Ï´Ù. Áß¿ëÀ» ÁöÅ°´Â °ÍÀÌ Áß¿äÇÒ µí ÇÕ´Ï´Ù. ÀÓ»ó°¡ÀÇ ÀÔÀå¿¡¼´Â...
Anubiscope
Confocal endomicroscopy tuided myotomy. º´ÀÌ ¾îµð¿¡ ÀÖ´ÂÁö ¾Ë ¼ö ÀÖ´Ù.
The third space
2) Broadening the applicability of ESD for EGC, technique or indication? (¼ÛÈ£ÁØ, ¼¿ï¾Æ»êº´¿ø)
¼ÛÈ£ÁØ ¼±»ý´ÔÀº ESD indicationÀÇ intermediate area°¡ ÀÖ´Ù´Â Á¡À» °Á¶ÇÏ¿´½À´Ï´Ù. 100% µ¿ÀÇÇսôÙ.
¼ÛÈ£ÁØ ¼±»ý´ÔÀº ¾Æ·¡ »çÁøÀ» º¸¿©ÁÖ¸é¼ Áú¹®À» ´øÁö¼Ì½À´Ï´Ù. ´äÀº ÁÖÁö ¾Ê¾ÒÁö¸¸... ÁÂÃø´Â 48¼¼ ¿©ÀÚ signet ring cell carcinoma¿´°í ¿ìÃøÀº 56¼¼ ³²ÀÚ poorly differentiated adenocarcinoma¿´½À´Ï´Ù.
Á¦ ³ª¸§ÀÇ ´äÀ» »ý°¢ÇØ º¸¾Ò½À´Ï´Ù. ¸ÕÀú ¿ìÃø 56¼¼ ³²ÀÚÀÇ °æ¿ì´Â °£´ÜÇÕ´Ï´Ù. ¼ö¼úÀÔ´Ï´Ù. Poorly differentiated adenocarcinoma´Â signet ring cell carcinomaº¸´Ù ¿©·¯ ¸éÀÌ ÁÁÁö ¾Ê½À´Ï´Ù. °æ°è ÆÇÁ¤°ú ½É´Þµµ ÆÇÁ¤ÀÌ ¾î·Æ°í ¸²ÇÁÀý ÀüÀ̵µ ´Ù¼Ò ¸¹Àº µí ÇÕ´Ï´Ù. Poorly differentiated adenocarcinomaÀÇ °æ¿ì´Â °ÅÀÇ ÀÚµ¿ÀûÀ¸·Î ¼ö¼úÀ» º¸³»°í ÀÖ½À´Ï´Ù.
¹®Á¦´Â ÁÂÃø signet ring cell carcinomaÀÔ´Ï´Ù. Á¦ ÆÇ´ÜÀº ¿©ÀüÈ÷ ¼ö¼úÀÔ´Ï´Ù. Signet ring cell carcinomaµµ Ä¡·áÇØ º¸¸é »ý°¢º¸´Ù Å« °æ¿ì°¡ ¸¹½À´Ï´Ù. ¸²ÇÁÀý ÀüÀ̵µ ¾øÁö ¾Ê½À´Ï´Ù. ´Ù¸¸ ÃÖ±Ù ¿©·¯ ¹®Çå°ú Àü¹®°¡ ÀÇ°ß°ú ÀúÈñÀÇ ºÐ¼®(2015³â ´ëÇѼÒȱâÇÐȸ¿¡ ÃÊ·ÏÀ» Á¦ÃâÇÏ¿´½À´Ï´Ù) µîÀ» °í·ÁÇÒ ¶§, 1 cm ÀÌÇÏÀÇ flatÇÑ signet ring cell carcinoma´Â ESD¸¦ °í·ÁÇÒ ¼ö ÀÖÀ» °Í °°´Ù´Â ´À³¦Àº °¡Áö°í ÀÖ½À´Ï´Ù. ¿¹»óµÇ´Â curative resection rate´Â 70% Á¤µµÀÔ´Ï´Ù. Non-curative resectionÀ̶ó´Â º´¸®°á°ú¶ó¸é ¹Ýµå½Ã ¼ö¼úÀ» ÇØ¾ß ÇÕ´Ï´Ù. ÁÂÃø 48¼¼ ¿©ÀÚ È¯ÀÚ¿¡ ´ëÇÑ ÀúÀÇ ÀÇ°ßÀº "¼ö¼úÀ» ÃßõÇ쵂 clinical trial setting¿¡¼ ȤÀº ±×¿¡ ÁØÇÑ »óȲ¿¡¼ ESD¸¦ ½ÃÇàÇÒ ¼ö ÀÖ´Ù"ÀÔ´Ï´Ù. ÇöÀç±îÁö signet ring cell carcinoma¿¡ ´ëÇÑ ESD¸¦ Ç¥ÁØ Ä¡·á·Î »ý°¢ÇÏÁö´Â ¾Ê°í ÀÖ½À´Ï´Ù. ºñÇ¥ÁØ Ä¡·á¸¦ ȯÀÚ¿¡°Ô Àû¿ëÇÒ ¶§¿¡´Â ¸Å¿ì ÁÖÀÇÇØ¾ß ÇÕ´Ï´Ù.
3) Endoscopic management for stircure and leakage (ÀÌÇ׶ô, ÇѾç´ëÇб³)
Long segment lye stricture¸¦ stentingÀ¸·Î Ä¡·áÇÑ »ç·Ê°¡ ÀλóÀûÀ̾ú½À´Ï´Ù. È޽Ľð£¿¡ ÀÌÇ׶ô ¼±»ý´Ô²² ¹®ÀÇÇÑ ¹Ù 3 Áõ·Ê°¡ ÀÖ¾ú°í 2¸íÀº ¾ÆÁÖ Àß µÇ¾ú°í 1¸íÀº õ°øÀÌ ¹ß»ýÇÏ¿´´Ù°í ÇÕ´Ï´Ù. ´ÙÇེ·´°Ô õ°ø 1¸íÀº ºñ¼ö¼úÀû Ä¡·á·Î È£ÀüµÇ¾ú´Ù°í Çϳ׿ä.
FIstula ȤÀº perforationÀ» Ä¡·áÇÏ´Â ¿©·¯ optionÀ» ¼³¸íÇØ Áּ̽À´Ï´Ù.
ÀÌ Áß OTSC (over the scope clip device)´Â ÇöÀç ±¹³»¿¡¼ »ç¿ëÇÒ ¼ö ¾ø´Â °ÍÀ¸·Î ¾Ë°í ÀÖ½À´Ï´Ù. 1ȸ¿ëÀ¸·Î 100¸¸¿ø Âë Çߴµ¥¿ä... ³ª¸§ À¯¿ë¼ºÀÌ ÀÖ¾úÁö¸¸ ºñ½Î´Ù´Â ÀÌÀ¯·Î ´ç±¹¿¡¼ no ÇÑ °Í °°½À´Ï´Ù. ¾ÈŸ±î¿î ÀÏÀÌ °è¼ÓµË´Ï´Ù. ¿ì¸®³ª¶ó¿¡¼´Â ½Ñ Ä¡·á¸¦ Àß ÇÏ´Â °ÍÀÌ ÁÁÀº Àǻ簡 µÇ´Â Áö¸§±æÀÔ´Ï´Ù. Á¶±Ý¸¸ ºñ½Î¸é ¹Ù·Î no µË´Ï´Ù. ÀÌ·±...
7. ³»½Ã°æÀû À¯¹®±Ù ÀýÁ¦¼ú. endoscopic pyloromyotomy (¿¬¼¼´ëÇб³ Á¤Çö¼ö)
POEM°ú °°Àº °³³äÀ» pylorus¿¡ Àû¿ëÇÑ ½Ã¼úÀÔ´Ï´Ù. °ú°Å¿¡ ´Ù¼Ò °¡º±°Ô ´Ù·ïÁö´ø pylorius°¡ ¾ÕÀ¸·Î´Â Áß¿äÇØÁú Àü¸ÁÀÔ´Ï´Ù.
2013³â Khashab µîÀÌ ´ç´¢º´¼º À§¸¶ºñ¿¡¼ ÃÖÃÊ·Î ½ÃÇàµÇ¾ú½À´Ï´Ù (Khashab. Gastrointest Endosc 2013). Á¤Çö¼ö ¼±»ý´ÔÀº ¼ö¼ú ÈÄ À§¸¶ºñ ȯÀÚ¿¡¼ ½ÃÇàÇÏ¿´½À´Ï´Ù. ¿¬¼¼´ëÇб³¿¡¼´Â Áö±Ý±îÁö ´ç´¢º´¼º À§¸¶ºñ¿Í ½ÄµµÀýÁ¦¼ú ÈÄ À§¸¶ºñ ȯÀÚ 12¸í¿¡¼ ½ÃÇàÇß´Ù°í ÇÕ´Ï´Ù. Mean emptying timeÀÌ 370ºÐ¿¡¼ 170ºÐÀ¸·Î 200ºÐ Á¤µµ ª¾ÆÁö´Âµ¥ Á¤»ó ¹üÀ§·Î µ¹¾Æ¿À´Â °æ¿ì´Â ¸¹Áö ¾Ê¾Ò½À´Ï´Ù.
Seohyun Lee(¼¿ï¾Æ»êº´¿ø)Àº ´ëÀå ESD¿¡¼ histologic lateral margin positivity¿¡ ´ëÇÑ Æ÷½ºÅÍ¿¡¼ lateral margin false positiveÀÇ ÀÌÀ¯¿Í À̸¦ ¸·±âÀ§ÇÑ tipÀ» ¼Ò°³ÇÏ¿´½À´Ï´Ù.
Jeong Wook Kim (Á߾Ӵ뺴¿ø)Àº hard sigmoid fecaloma¸¦ Coca-cola injection ÈÄ snaringÀ¸·Î Á¦°ÅÇÑ Áõ·Ê¸¦ ¼Ò°³ÇÏ¿´½À´Ï´Ù. ³¿»õ°¡ ¸¹ÀÌ ³µÀ» °Í °°½À´Ï´Ù.^^
In Ji Song (¿¬¼¼´ëº´¿ø)Àº ESD ÈÄ additional gastrectomy¿¡ ´ëÇÑ predictive modelÀ» ¼Ò°³Çß½À´Ï´Ù.
À§ fundusÀÇ 1 cm SMT¿¡ ´ëÇÏ¿© EUS ÈÄ ESD¸¦ ½ÃÇàÇÑ Áõ·Ê°¡ ¼Ò°³µÇ¾ú½À´Ï´Ù. Àú´Â 'À§ fundusÀÇ 1 cm SMT´Â EUS ÀûÀÀÁõÀÌ ¾Æ´Ï´Ù'´Â ÀÇ°ßÀ» ¹àÇû½À´Ï´Ù. ¿©·¯ ¼±»ý´Ôµé²²¼ ¹Ý´ëÀÇ°ßÀ» ¸»¾¸Çϼ̽À´Ï´Ù. ¿ÏÀüÈ÷ Äڳʿ¡ ¸ô¸° ´À³¦... ±×·±µ¥ ³î¶ó¿î °ÍÀº È޽Ľð£¿¡ ¶Ç ´Ù¸¥ ¿©·¯ ¼±»ý´Ôµé²²¼ Àú¸¦ ã¾Æ¿Í °Ý·ÁÇØ Á̴ּٴ °ÍÀÔ´Ï´Ù. Àú¿Í °°Àº ÀÇ°ßÀ» °¡Áö°í °è½Å´Ù¸é¼... Àü¹®°¡ »çÀÌ¿¡¼µµ EUS´Â È£ºÒÈ£°¡ ¸í¹éÈ÷ °¥¸³´Ï´Ù. ÇÐȸÀå¿¡¼´Â EUS¸¦ »ç¶ûÇÏ´Â ¼±»ý´Ôµé¸¸ ¹ß¾ðÇϱ⠶§¹®¿¡ ±× Çʿ伺ÀÌ °ú´ëÆò°¡µÇÁö¸¸, ÇöÀåÀÇ ¿©·¯ °í¼öµéÀº ÇÐȸÀåÀÇ µé¶á ºÐÀ§±â¿¡ ÈÛ¾µ¸®Áö ¾Ê°í ¹¬¹¬È÷ ÀûÀýÇÑ ÀûÀÀÁõÀ» ÁöÅ°°í °è½Å °Í °°½À´Ï´Ù. Âü ´ÙÇེ·¯¿î ÀÏÀÔ´Ï´Ù. Àú´Â ȯÀÚ¸¦ »ç¶ûÇÏÁö¸¸ EUS¸¦ »ç¶ûÇÏÁö´Â ¾Ê½À´Ï´Ù. ÇÊ¿äÇÒ ¶§ ÀÌ¿ëÇÒ »ÓÀÔ´Ï´Ù.
IDENÀÇ ¿©·¯ °ÀǸ¦ µéÀ¸¸é¼ Á¦°¡ ¹«Ã´ ³°Àº »ç¶÷ÀÌ µÇ¾î¹ö¸° ´À³¦À̾ú½À´Ï´Ù. Submucosal tunnelingÀ» ÀÌ¿ëÇÑ third space¿¡¼ ÀÏÇÏ´Â pioneerµéÀÌ Âü ¸¹´õ±º¿ä. ¹Ý¸é¿¡ Àú´Â 'first spaceÀÎ À§Á¡¸·¿¡¼ endoscopic submucosal dissection (ESD)À̶ó´Â »·ÇÏ°í ³°Àº ½Ã¼úÀ» ÇàÇÏ´Â Åð¹°'ÀÌ µÈ µíÇÑ ±âºÐÀ» ¶³Ä¡±â ¾î·Á¿ü½À´Ï´Ù. ÀÌ Æй谨À» ¾î¶»°Ô ±Øº¹ÇØ¾ß ÇÒÁö... Àú¸¦ ã´Â ȯÀÚÀÇ 99.9%´Â first space¿¡¼ Ä¡·áÇÒ ¼ö ÀÖ°í, 0.1% ȤÀº ±× ÀÌÇÏ¿¡¼ third space Ä¡·á°¡ ÇÊ¿äÇÒ °Í °°½À´Ï´Ù. Third space´Â ¾î¼´Ù Çѹø µé¾î°¡°í Æò¼Ò¿¡´Â ±×³É first space¸¦ Áöų±î ÇÕ´Ï´Ù. Àú´Â ±×³É ´Ã ÇÏ´ø ESD¸¦ Á» ´õ Àß ÇÒ±î ÇÕ´Ï´Ù. Á¦¹ß ESD¸¦ ¹ö¸®Áö ¸»¾ÆÁÖ¼¼¿ä.
2015³â 6¿ù 20ÀϺÎÅÍ 21ÀϱîÁö ¼¿ï Grand Hilton È£ÅÚ¿¡¼ IDEN 2015ÀÌ ¿¸± °èȹÀ̾ú½À´Ï´Ù. Àú´Â ù ³¯ ù ¼¼¼Ç¿¡ °ÀÇ°¡ ÀÖ¾ú½À´Ï´Ù. ±×·¯³ª MERS »çÅ·ΠÀÎÇÏ¿© 9¿ù·Î Çà»ç°¡ ¿Å°ÜÁö¸é¼ Á¦ ¼¼¼ÇÀÌ »ç¶óÁ³½À´Ï´Ù. ¿Ü±¹ÀÎ ¿¬ÀÚµéÀÌ Âü¼®ÀÌ ºÒ°¡´ÉÇØÁ³±â ¶§¹®ÀÔ´Ï´Ù. °á±¹ Breakfast with the Experts ¼¼¼ÇÀ¸·Î º¯°æµÇ¾ú½À´Ï´Ù.